Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Preclinical Results
Portfolio Pulse from Benzinga Newsdesk
Scinai Immunotherapeutics has reported preclinical results for its innovative plaque psoriasis treatment, NanoAbs. The treatment has shown to downregulate key molecular markers overexpressed in plaque psoriasis and helped the stratum corneum regain a normal appearance in a laboratory 3D skin model. Results from an ex-vivo study in human psoriatic skin are expected in Q4 2023, and in-vivo animal study results are anticipated in early 2024.
September 13, 2023 | 8:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Scinai's NanoAbs treatment for plaque psoriasis has shown promising preclinical results. The company expects results from further studies in Q4 2023 and early 2024.
The news is directly related to Scinai and its product, NanoAbs. The positive preclinical results could boost investor confidence in the company's research and development capabilities, potentially leading to a short-term increase in the company's stock price. However, the final impact will depend on the results of the upcoming studies.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100